Summary

US Tissue Engineered Skin Substitutes Market is valued approximately USD 278.62 million in 2023 and is anticipated to grow with a healthy growth rate of more than 5.47% over the forecast period 2024-2032. Tissue-engineered skin substitutes are advanced biomedical devices that are designed to replace damaged skin tissue. When conventional grafts are impractical, they are used to treat severe burns, long-term wounds, and skin disorders. These replacements imitate the layers and functions of normal skin by combining biocompatible materials with live cells from the patient or donors. They are available in three varieties: acellular forms that include proteins and growth factors for healing, live cells for regeneration in cell-based versions, and composite versions that combine the two. These replacements represent a major development in wound care and regenerative medicine, providing less donor site complications, enhanced aesthetics, and quicker healing times. The rise in adoption of regenerative medicine and advanced biotechnology in skin repair and wound care is a key trend for the US Tissue Engineered Skin Substitutes Market. This trend is driven by the demand for innovative solutions that promote faster healing, reduce scarring, and improve overall patient outcomes.

The US Tissue Engineered Skin Substitutes Market share driven by a growing prevalence of chronic wounds, supportive reimbursement policies, and an aging population. The region's focus on effective therapies for conditions like diabetes is fueling a surge in demand for tissue engineered skin substitutes as it offers advanced wound care solutions, leading to improved healing outcomes. According to data from the American Diabetes Association, in 2021, approximately 38.4 million Americans, representing 11.6% of the population, were living with diabetes. Among them, 2 million had type 1 diabetes, with about 304,000 being children and adolescents. Of the total adults with diabetes, 29.7 million were diagnosed, while 8.7 million were undiagnosed. Also, the rising sports injuries, road accidents, and the presence of major industry players are further attributing to the demand of the tissue engineered skin substitutes. Furthermore, the region benefits from a skilled workforce and advancements in healthcare infrastructure, both of which are projected to drive market expansion in the anticipated years. However, lack of feasible reimbursement policies, coupled with the inability of reproducing skin appendages is expected to stifle US Tissue Engineered Skin Substitutes Market growth between 2022 and 2032.



Major market player included in this report are:
Amarantus Bioscience Holdings, Inc.
Organogenesis, Inc.
Kinetic Concepts, Inc.
Company 4
Company 5
Company 6
Company 7
Company 8
Company 9
Company 10



The detailed segments and sub-segment of the market are explained below:

By Product Type
Natural
Synthetic

By Application
Chronic Wounds
Acute Wounds

By End User
Hospital and Clinic
Ambulatory Surgical Center
Others


Years considered for the study are as follows:
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032

Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and Country level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market

ページTOPに戻る

Table of Contents

Chapter 1. US Tissue Engineered Skin Substitutes Market Definition and Research Assumptions
1.1. Research Objective
1.2. Market Definition
1.3. Research Assumptions
1.3.1. Inclusion & Exclusion
1.3.2. Limitations
1.3.3. Supply Side Analysis
1.3.3.1. Availability
1.3.3.2. Infrastructure
1.3.3.3. Regulatory Environment
1.3.3.4. Market Competition
1.3.3.5. Economic Viability (Consumer’s Perspective)
1.3.4. Demand Side Analysis
1.3.4.1. Regulatory frameworks
1.3.4.2. Technological Advancements
1.3.4.3. Environmental Considerations
1.3.4.4. Consumer Awareness & Acceptance
1.4. Estimation Methodology
1.5. Years Considered for the Study
1.6. Currency Conversion Rates

Chapter 2. Executive Summary
2.1. US Tissue Engineered Skin Substitutes Market Size & Forecast (2022- 2032)
2.2. Segmental Summary
2.2.1. By Product Type
2.2.2. By Application
2.2.3. By End User
2.3. Key Trends
2.4. Recession Impact
2.5. Analyst Recommendation & Conclusion
Chapter 3. US Tissue Engineered Skin Substitutes Market Dynamics
3.1. Market Drivers
3.2. Market Challenges
3.3. Market Opportunities
Chapter 4. US Tissue Engineered Skin Substitutes Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. US Tissue Engineered Skin Substitutes Market Size & Forecasts by Product Type 2022-2032
5.1. Natural
5.2. Synthetic
Chapter 6. US Tissue Engineered Skin Substitutes Market Size & Forecasts by Application 2022-2032
6.1. Chronic Wounds
6.2. Acute Wounds
Chapter 7. US Tissue Engineered Skin Substitutes Market Size & Forecasts by End User 2022-2032
7.1. Hospital and Clinic
7.2. Ambulatory Surgical Center
7.3. Others
Chapter 8. Competitive Intelligence
8.1. Key Company SWOT Analysis
8.1.1. Company 1
8.1.2. Company 2
8.1.3. Company 3
8.2. Top Market Strategies
8.3. Company Profiles
8.3.1. Amarantus Bioscience Holdings, Inc.
8.3.1.1. Key Information
8.3.1.2. Overview
8.3.1.3. Financial (Subject to Data Availability)
8.3.1.4. Product Summary
8.3.1.5. Market Strategies
8.3.2. Organogenesis, Inc.
8.3.3. Kinetic Concepts, Inc.
8.3.4. Company 4
8.3.5. Company 5
8.3.6. Company 6
8.3.7. Company 7
8.3.8. Company 8
8.3.9. Company 9
8.3.10. Company 10
Chapter 9. Research Process
9.1. Research Process
9.1.1. Data Mining
9.1.2. Analysis
9.1.3. Market Estimation
9.1.4. Validation
9.1.5. Publishing
9.2. Research Attributes